

# Feline hypertension assessment record

Cat's name  Owner's last name   
 Assessment date       Cat's age

## Hypertension risk factors

Associated diseases	<input type="radio"/> Chronic kidney disease (CKD)	<input type="radio"/> Hyperthyroidism			
	<input type="radio"/> Hyperaldosteronism (Conn's)	<input type="radio"/> Other <small>Please describe:</small>			
	<input type="radio"/> Idiopathic	<input type="radio"/> Not investigated			
Target organ assessment	Eyes <small>(e.g. blindness, retinal detachment)</small>	<input type="radio"/> Normal	<input type="radio"/> Abnormal	<input type="radio"/> Not assessed	<small>If abnormal please describe:</small>
	Brain <small>(e.g. seizures, behavioural changes)</small>	<input type="radio"/> Normal	<input type="radio"/> Abnormal	<input type="radio"/> Not assessed	<small>If abnormal please describe:</small>
	Kidneys <small>(e.g. elevated SDMA &amp;/or creatinine, proteinuria)</small>	<input type="radio"/> Normal	<input type="radio"/> Abnormal	<input type="radio"/> Not assessed	<small>If abnormal please describe:</small>
	Heart <small>(e.g. left ventricular hypertrophy, gallop sounds)</small>	<input type="radio"/> Normal	<input type="radio"/> Abnormal	<input type="radio"/> Not assessed	<small>If abnormal please describe:</small>

Is there evidence of target organ damage?  Yes  No      Is the cat aged 9 years or older?  Yes  No

## Systolic blood pressure (SBP) measurement

Should be performed in a calm, quiet room after at least a 5-10 minute acclimatisation period.

Acclimatisation period (mins)	<input type="text"/>	Room used	<input type="text"/>
Was the owner present?	<input type="radio"/> Yes <input type="radio"/> No		
Person(s) performing SBP measurement	<input type="text"/>		
Position of the cat	<input type="radio"/> Standing <input type="radio"/> Sitting <input type="radio"/> Sternal <input type="radio"/> Lateral		
Other notes regarding assessment <small>(e.g. cat's stress level)</small>	<input type="text"/>		

### Technique

Doppler       High definition oscillometry (HDO)

Cuff size <small>(ideal width 30-40% of limb/ tail circumference)</small>	<input type="text"/>	Measurement site <small>(e.g. left forelimb, right hindlimb, tail)</small>	<input type="text"/>
--	----------------------	---	----------------------

### Measurements (mmHg)

Take up to 10 readings then discard the first measurement. Circle the most consistent 5-7 readings and use these to calculate the mean SBP.

1. <input type="text"/>	2. <input type="text"/>	3. <input type="text"/>	4. <input type="text"/>	5. <input type="text"/>
6. <input type="text"/>	7. <input type="text"/>	8. <input type="text"/>	9. <input type="text"/>	10. <input type="text"/>

Mean average of 5-7 SBP measurements:  (mmHg)



# Feline hypertension management plan

Based on ACVIM guidelines, this easy-to-follow guide helps you identify cats at risk of hypertension, monitor them effectively and decide when to start treatment.<sup>1</sup>

## Cats are at risk of hypertension if they:




Have evidence of target organ damage (TOD)

OR



Have a disease associated with hypertension, e.g. chronic kidney disease (CKD) or hyperthyroidism

OR



Are aged 9 years or older

## For cats at risk



<sup>1</sup>The target SBP range is between 120–140 mmHg.  
<sup>2</sup>After 4 weeks, the dose of Semintra may be reduced in cats with SBP of <140 mmHg (in 0.5 mg/kg increments), at the vet's discretion. If SBP increases over the course of the disease, the daily dose may be increased again up to 2 mg/kg.<sup>2</sup> In cats with hypertension associated with CKD, the recommended effective dose is not lower than 1 mg/kg.<sup>2</sup> Adapted from ACVIM guidelines, Acierno, *et al.* 2018.<sup>1</sup>

Treatment plan

Re-assessment date

**Semintra 10 mg/ml oral solution for cats.** Active substance: Telmisartan. Uses: Treatment of systemic hypertension in cats. Further information: Please refer to the product packaging and leaflets for information about side effects, precautions, warnings and contra-indications. Legal category: UK: POM-V IE: POM. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: 01344 746959 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). Email: [vetenquiries@boehringer-ingelheim.com](mailto:vetenquiries@boehringer-ingelheim.com). Semintra is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. © 2019 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Apr 2019. AHD12156. Use Medicines Responsibly.

References: 1. Acierno MJ, *et al. J Vet Intern Med.* 2018;1-20. 2. Semintra Summary of Product Characteristics. 2018.



**Semintra**  
THE SOLUTION